Skip to main content
. Author manuscript; available in PMC: 2013 Nov 18.
Published in final edited form as: Neuroreport. 2012 Jul 11;23(10):10.1097/WNR.0b013e328354f5c1. doi: 10.1097/WNR.0b013e328354f5c1

Figure 1.

Figure 1

(A) Quantitative RT-PCR of receptor mRNA levels in target brain regions. Compared to low-activity rats (LCR), high-activity rats (HCR) have greater expression of MC 3, 4, and 5 receptors (MC3R, MC4R, MC5R) in the paraventricular nucleus (PVN) and perifornical lateral hypothalamus (PeFLH). MC3R in PeFLH: HCR (N=8), LCR (N=8), MC4R in PeFLH: HCR (N=7), LCR (N=8), MC5R in PeFLH: HCR (N=8), LCR (N=8), MC3R in PVN: HCR (N=8), LCR (N=8), MC4R in PVN: HCR (N=7), LCR (N=8), MC5R in PVN: HCR (N=5), LCR (N=8). (B) Intra-PVN microinjections of MCR agonist Melanotan II (MTII) induced physical activity in male Sprague-Dawley (SD) rats (N=4); no effect was found after intra-PeFLH injections (data not shown). (C) Intra-PVN MTII-induced activity was significantly greater in high-activity rats (HCR, N=4) compared to low-activity rats (LCR, N=5). *p <0.05, NS: not significant.